Dual-energy X-ray absorptiometry (DXA) is the gold standard method for measuring bone
mineral density (BMD) which is most strongly associated with fracture risk. BMD is therefore …

Background Romosozumab, a fully humanized anti-sclerostin-antibody, is a bone-builder
stimulating osteoblasts and inhibiting osteoclast by activation of the canonical Wnt-beta …

Osteoanabolic-first treatment sequences are superior to oral bisphosphonates for fracture
reduction and BMD gain. However, data comparing osteoanabolic medications with the …

The overarching goal of osteoporosis management is to prevent fractures. A goal-directed
approach to long-term management of fracture risk helps ensure that the most appropriate …

Romosumab (ROMO) should be used to treat postmenopausal women with osteoporosis at
high fracture risk after carefully considering the cardiovascular status and the risk/benefit …

The contemporary treatment of osteoporosis has seen tremendous evolution. Today, we
have access to powerful biologic agents for the treatment of osteoporosis and an improved …